The prevalent c.903+469T>C mutation in MTRR causes the cblE type of homocystinuria by strengthening an SRSF1 binding site in an ESE leading to activation of a pseudoexon. We hypothesized that other splicing regulatory elements (SREs) are also critical for MTRR pseudoexon inclusion. We demonstrate that the MTRR pseudoexon is on the verge of being recognized and is therefore vulnerable to several point mutations that disrupt a fine-tuned balance between the different SREs. Normally, pseudoexon inclusion is suppressed by a hnRNP A1 binding exonic splicing silencer (ESS). When the c.903+469T>C mutation is present two ESEs abrogate the activity of the ESS and promote pseudoexon inclusion. Blocking the 3'splice site or the ESEs by SSOs is effective in restoring normal splicing of minigenes and endogenous MTRR transcripts in patient cells. By employing an SSO complementary to both ESEs, we were able to rescue MTRR enzymatic activity in patient cells to approximately 50% of that in controls. We show that several point mutations, individually, can activate a pseudoexon, illustrating that this mechanism can occur more frequently than previously expected. Moreover, we demonstrate that SSO blocking of critical ESEs is a promising strategy to treat the increasing number of activated pseudoexons.

Department of Biochemistry and Molecular Biology and the Villum Center for Bioanalytical Sciences University of Southern Denmark Odense M Denmark

Division of Metabolism University Children's Hospital Zürich Switzerland

Institute of Inherited Metabolic Disorders Charles University Prague 1st Faculty of Medicine and General University Hospital Praha Czech Republic

See more in PubMed

Shapiro M.B., Senapathy P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res. 1987;15:7155–7174. PubMed PMC

Roca X., Olson A.J., Rao A.R., Enerly E., Kristensen V.N., Borresen-Dale A.L., Andresen B.S., Krainer A.R., Sachidanandam R. Features of 5′-splice-site efficiency derived from disease-causing mutations and comparative genomics. Genome Res. 2008;18:77–87. PubMed PMC

Buratti E., Baralle M., Baralle F.E. Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucleic Acids Res. 2006;34:3494–510. PubMed PMC

Cartegni L., Chew S.L., Krainer A.R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 2002;3:285–298. PubMed

Dreyfuss G., Kim V.N., Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat. Rev. Mol. Cell. Biol. 2002;3:195–205. PubMed

Lim K.H., Ferraris L., Filloux M.E., Raphael B.J., Fairbrother W.G. Using positional distribution to identify splicing elements and predict pre-mRNA processing defects in human genes. Proc. Natl. Acad. Sci. U. S. A. 2011;108:11093–11098. PubMed PMC

Sterne-Weiler T., Howard J., Mort M., Cooper D.N., Sanford J.R. Loss of exon identity is a common mechanism of human inherited disease. Genome Res. 2011;21:1563–1571. PubMed PMC

Matern D., He M., Berry S.A., Rinaldo P., Whitley C.B., Madsen P.P., van Calcar S.C., Lussky R.C., Andresen B.S., Wolff J.A., et al. Prospective diagnosis of 2-methylbutyryl-CoA dehydrogenase deficiency in the Hmong population by newborn screening using tandem mass spectrometry. Pediatrics. 2003;112:74–78. PubMed

Wang G.S., Cooper T.A. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat. Rev. Genet. 2007;8:749–761. PubMed

Andresen B.S., Krainer A.R. When the genetic code is not enough-How sequence variation can affect pre-mRNA splicing and cause (complex) disease. In: Almasy L, Al-Chalabi A, editors. Genetics of Complex Human Diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009. pp. 165–182.

Dobrowolski S.F., Andersen H.S., Doktor T.K., Andresen B.S. The PAH c.30C>G synonymous variation (p.G10G) creates a common exonic splicing silencer. Mol. Genet. Metab. 2010;100:316–323. PubMed

Heintz C., Dobrowolski S.F., Andersen H.S., Demirkol M., Blau N., Andresen B.S. Splicing of phenylalanine hydroxylase (PAH) exon 11 is vulnerable - Molecular pathology of mutations in PAH exon 11. Mol. Genet. Metab. 2012;106:403–411. PubMed

Olsen R.K.J., Brøner S., Sabaratnam R., Doktor T.K., Andersen H.S., Bruun G.H., Gahrn B., Stenbroen V., Olpin S.E., Dobbie A., et al. The ETFDH c.158A>G variant disrupts the balanced interplay of ESE- and ESS-binding proteins thereby causing missplicing and multiple acyl-CoA dehydrogenation deficiency. Hum. Mutat. 2014;35:86–95. PubMed

Sun H., Chasin L.A. Multiple splicing defects in an intronic false exon. Mol. Cell. Biol. 2000;20:6414–6425. PubMed PMC

Sironi M., Menozzi G., Riva L., Cagliani R., Comi G.P., Bresolin N., Giorda R., Pozzoli U. Silencer elements as possible inhibitors of pseudoexon splicing. Nucleic Acids Res. 2004;32:1783–1791. PubMed PMC

Zhang X.H., Chasin L.A. Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev. 2004;18:1241–1250. PubMed PMC

Dhir A., Buratti E. Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies. FEBS. J. 2010;277:841–855. PubMed

Homolova K., Zavadakova P., Doktor T.K., Schroeder L.D., Kozich V., Andresen B.S. The deep intronic c.903+469T>C mutation in the MTRR gene creates an SF2/ASF binding exonic splicing enhancer, which leads to pseudoexon activation and causes the cblE type of homocystinuria. Hum. Mutat. 2010;31:437–444. PubMed PMC

Ishii S., Nakao S., Minamikawa-Tachino R., Desnick R.J., Fan J.Q. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am. J. Hum. Genet. 2002;70:994–1002. PubMed PMC

King K., Flinter F.A., Nihalani V., Green P.M. Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome. Hum. Genet. 2002;111:548–554. PubMed

Pagani F., Buratti E., Stuani C., Bendix R., Dork T., Baralle F.E. A new type of mutation causes a splicing defect in ATM. Nat. Genet. 2002;30:426–429. PubMed

Rincon A., Aguado C., Desviat L.R., Sánchez-Alcudia R., Ugarte M., Pérez B. Propionic and methylmalonic acidemia: antisense therapeutics for intronic variations causing aberrantly spliced messenger RNA. Am. J. Hum. Genet. 2007;81:1262–1270. PubMed PMC

Faà V., Incani F., Meloni A., Corda D., Masala M., Baffico A.M., Seia M., Cao A., Rosatelli M.C. Characterization of a disease-associated mutation affecting a putative splicing regulatory element in intron 6b of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. J. Biol. Chem. 2009;284:30024–30031. PubMed PMC

Davis R.L., Homer V.M., George P.M., Brennan S.O. A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment. Hum. Mutat. 2009;30:221–227. PubMed

Yamaguchi H., Fujimoto T., Nakamura S., Ohmura K., Mimori T., Matsuda F., Nagata S. Aberrant splicing of the milk fat globule-EGF factor 8 (MFG-E8) gene in human systemic lupus erythematosus. Eur. J. Immunol. 2010;40:1778–2085. PubMed

Maquat L.E. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol. Cell. Biol. 2004;5:89–99. PubMed

Wilson A., Leclerc D., Rosenblatt D.S., Gravel R.A. Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism. Hum. Mol. Genet. 1999;8:2009–2016. PubMed

Zavadakova P., Fowler B., Suormala T., Novotna Z., Mueller P., Hennermann J.B., Zeman J., Vilaseca M.A., Vilarinho L., Gutsche S., et al. cblE Type of homocystinuria due to methionine synthase reductase deficiency: Functional correction by minigene expression. Hum. Mutat. 2005;25:239–247. PubMed

Huemer M., Bürer C., Ješina P., Kožich V., Landolt M.A., Suormala T., Fowler B., Augoustides-Savvopoulou P., Blair E., Brennerova, et al. Clinical onset and course, response to treatment and outcome in 24 patients with the cblE or cblG remethylation defect complemented by genetic and in vitro enzyme study data. J. Inherit. Metab. Dis. 2014 doi:10.1007/s10545–014–9803–7. PubMed

Perez B., Rodriguez-Pascau L., Vilageliu L., Grinberg D., Ugarte M., Desviat L.R. Present and future of antisense therapy for splicing modulation in inherited metabolic disease. J. Inherit. Metab. Dis. 2010;33:397–403. PubMed

Havens M.A., Duelli D.M., Hastings M.L. Targeting RNA splicing for disease therapy. Wiley Interdiscip. Rev. RNA. 2013;4:247–266. PubMed PMC

Singh G., Cooper T.A. Minigene reporter for identification and analysis of cis elements and trans factors affecting pre-mRNA splicing. Biotechniques. 2006;41:177–181. PubMed

Nielsen K.B., Sorensen S., Cartegni L., Corydon T.J., Doktor T.K., Schroeder L.D., Reinert L.S., Elpeleg O., Krainer A.R., Gregersen N., et al. Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am. J. Hum. Genet. 2007;80:416–432. PubMed PMC

Fowler B., Jakobs C. Post- and prenatal diagnostic methods for the homocystinurias. Eur. J. Pediatr. 1998;157(Suppl 2):S88–S93. PubMed

Coelho D., Kim J.C., Miousse I.R., Fung S., du Moulin M., Buers I., Suormala T., Burda P., Frapolli M., Stucki M., et al. Mutations in ABCD4 cause a new inborn error of vitamin B12 metabolism. Nat. Genet. 2012;44:1152–1155. PubMed

Cartegni L., Wang J., Zhu Z., Zhang M.Q., Krainer A.R. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res. 2003;31:3568–3571. PubMed PMC

Quinlan A.R., Hall I.M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841–842. PubMed PMC

Cartegni L., Hastings M.L., Calarco J.A., de Stanchina E., Krainer A.R. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am. J. Hum. Genet. 2006;78:63–77. PubMed PMC

Ghigna C., De Toledo M., Bonomi S., Valacca C., Gallo S., Apicella M., Eperon I., Tazi J., Biamonti G. Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biol. 2010;7:495–503. PubMed

Ghigna C., Giordano S., Shen H., Benvenuto F., Castiglioni F., Comoglio P.M., Green M.R., Riva S., Biamonti, G. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol. Cell. 2005;20:881–890. PubMed

Gonçalves V., Theisen P., Antunes O., Medeira A., Ramos J.S., Jordan P., Isidro G. A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14. Mutat. Res. 2009;662:33–36. PubMed

Okunola H.L., Krainer A,R. Cooperative-binding and splicing-repressive properties of hnRNP A1. Mol. Cell. Biol. 2009;29:5620–5631. PubMed PMC

Mayeda A., Helfman D.M., Krainer A.R. Modulation of exon skipping and inclusion by heterogeneous nuclear ribonucleoprotein A1 and pre-mRNA splicing factor SF2/ASF. Mol. Cell. Biol. 1993;13:2993–3001. PubMed PMC

Pollard A.J., Krainer A.R., Robson S.C., Europe-Finner G.N. Alternative splicing of the adenylyl cyclase stimulatory G-protein G alpha(s) is regulated by SF2/ASF and heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) and involves the use of an unusual TG 3′-splice Site. J. Biol. Chem. 2002;277:15241–15251. PubMed

Bonomi S., di Matteo A., Buratti E., Cabianca D.S., Baralle F.E., Ghigna C., Biamonti G. HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition. Nucleic Acids Res. 2013;41:8665–8679. PubMed PMC

Lappalainen T., Sammeth M., Friedländer M.R., ‘t Hoen P.A., Monlong J., Rivas M.A., Gonzàlez-Porta M., Kurbatova N., Griebel T., Ferreira P.G., et al. Transcriptome and genome sequencing uncovers functional variation in humans. Nature. 2013;501:506–511. PubMed PMC

Katz Y., Wang E.T., Airoldi E.M., Burge C.B. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat. Methods. 2010;7:1009–1015. PubMed PMC

Stucki M., Suormala T., Fowler B., Valle D., Baumgartner M.R. Cryptic exon activation by disruption of exon splice enhancer: novel mechanism causing 3-methylcrotonyl-CoA carboxylase deficiency. J. Biol. Chem. 2009;284:28953–28957. PubMed PMC

van Deutekom J.C., Bremmer-Bout M., Janson A.A., Ginjaar I.B., Baas F., den Dunnen J.T., van Ommen G.J. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum. Mol. Genet. 2001;10:1547–1554. PubMed

Perez B., Rincon A., Jorge-Finnigan A., Richard E., Merinero B., Ugarte M., Desviat L.R. Pseudoexon exclusion by antisense therapy in methylmalonic aciduria (MMAuria) Hum. Mutat. 2009;30:1676–1682. PubMed

Rodríguez-Pascau L., Coll M.J., Vilageliu L., Grinberg D. Antisense oligonucleotide treatment for a pseudoexon-generating mutation in the NPC1 gene causing Niemann-Pick type C disease. Hum. Mutat. 2009;30:E993–E1001. PubMed

Vega A.I., Pérez-Cerdá C., Desviat L.R., Matthijs G., Ugarte M., Pérez B. Functional analysis of three splicing mutations identified in the PMM2 gene: toward a new therapy for congenital disorder of glycosylation type Ia. Hum. Mutat. 2009;30:795–803. PubMed

Hua Y., Sahashi K., Hung G., Rigo F., Passini M.A., Bennett C.F., Krainer A.R. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010;24:1634–1644. PubMed PMC

Blázquez L., Aiastui A., Goicoechea M., Martins de Araujo M., Avril A., Beley C., García L., Valcárcel J., Fortes P., López de Munain A. In vitro correction of a pseudoexon-generating deep intronic mutation in LGMD2A by antisense oligonucleotides and modified small nuclear RNAs. Hum. Mutat. 2013;34:1387–1395. PubMed